vs

Side-by-side financial comparison of InMode Ltd. (INMD) and IRIDEX CORP (IRIX). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $93.2K, roughly 158.0× InMode Ltd.).

Mode Media, Inc., was a digital lifestyle media company operating a suite of websites where content was produced by anyone but reviewed by professional editors prior to publishing. In 2013, Mode Media had a valuation of about $1 billion as the company prepped for an IPO. In 2015, Mode Media had grown to over $100 million in revenue, primarily from providing native content, branded video and digital advertising to large brands but had over $100 million in expenses.

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

INMD vs IRIX — Head-to-Head

Bigger by revenue
IRIX
IRIX
158.0× larger
IRIX
$14.7M
$93.2K
INMD

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
INMD
INMD
IRIX
IRIX
Revenue
$93.2K
$14.7M
Net Profit
$21.9K
Gross Margin
77.6%
37.2%
Operating Margin
Net Margin
23.5%
Revenue YoY
-69.7%
Net Profit YoY
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INMD
INMD
IRIX
IRIX
Q4 25
$14.7M
Q3 25
$93.2K
$12.5M
Q2 25
$95.6K
$13.6M
Q1 25
$77.9K
$11.9M
Q4 24
$12.7M
Q3 24
$130.2K
$11.6M
Q2 24
$86.4K
$12.6M
Q1 24
$80.3K
$11.8M
Net Profit
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
$21.9K
$-1.6M
Q2 25
$26.7K
$-994.0K
Q1 25
$18.2K
$-1.7M
Q4 24
$-834.0K
Q3 24
$51.0K
$-1.9M
Q2 24
$23.8K
$-2.7M
Q1 24
$23.7K
$-3.5M
Gross Margin
INMD
INMD
IRIX
IRIX
Q4 25
37.2%
Q3 25
77.6%
32.1%
Q2 25
80.0%
34.5%
Q1 25
78.2%
42.5%
Q4 24
44.0%
Q3 24
81.5%
37.3%
Q2 24
80.2%
40.7%
Q1 24
79.6%
37.9%
Operating Margin
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
-11.3%
Q2 25
-6.9%
Q1 25
-1.7%
Q4 24
-3.9%
Q3 24
-16.1%
Q2 24
-20.9%
Q1 24
-28.0%
Net Margin
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
23.5%
-12.6%
Q2 25
28.0%
-7.3%
Q1 25
23.4%
-14.2%
Q4 24
-6.6%
Q3 24
39.2%
-16.7%
Q2 24
27.6%
-21.2%
Q1 24
29.5%
-29.5%
EPS (diluted)
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
$-0.09
Q2 25
$-0.06
Q1 25
$-0.10
Q4 24
$-0.05
Q3 24
$-0.12
Q2 24
$-0.16
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INMD
INMD
IRIX
IRIX
Cash + ST InvestmentsLiquidity on hand
$155.3K
$6.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$703.8K
Total Assets
$785.7K
$29.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INMD
INMD
IRIX
IRIX
Q4 25
$6.0M
Q3 25
$155.3K
$5.6M
Q2 25
$155.3K
$6.8M
Q1 25
$155.3K
$7.2M
Q4 24
$2.4M
Q3 24
$144.4K
$3.9M
Q2 24
$144.4K
$4.1M
Q1 24
$144.4K
$5.4M
Total Debt
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
$703.8K
$4.7M
Q2 25
$703.8K
$6.1M
Q1 25
$703.8K
$852.0K
Q4 24
$2.1M
Q3 24
$787.4K
$2.6M
Q2 24
$787.4K
$4.2M
Q1 24
$787.4K
$6.5M
Total Assets
INMD
INMD
IRIX
IRIX
Q4 25
$29.2M
Q3 25
$785.7K
$28.4M
Q2 25
$785.7K
$31.6M
Q1 25
$785.7K
$34.2M
Q4 24
$29.1M
Q3 24
$863.3K
$30.2M
Q2 24
$863.3K
$31.2M
Q1 24
$863.3K
$34.1M
Debt / Equity
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INMD
INMD
IRIX
IRIX
Operating Cash FlowLast quarter
$24.5K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.12×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
$24.5K
$-1.2M
Q2 25
$24.1K
$-397.0K
Q1 25
$14.0K
$-1.1M
Q4 24
$-1.2M
Q3 24
$34.0K
$-3.1M
Q2 24
$42.1K
$-1.3M
Q1 24
$24.1K
$-1.6M
Free Cash Flow
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
$-1.2M
Q2 25
$-410.0K
Q1 25
$-1.2M
Q4 24
$-1.2M
Q3 24
$-3.1M
Q2 24
Q1 24
$-1.7M
FCF Margin
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
-9.4%
Q2 25
-3.0%
Q1 25
-9.8%
Q4 24
-9.8%
Q3 24
-26.5%
Q2 24
Q1 24
-14.0%
Capex Intensity
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
INMD
INMD
IRIX
IRIX
Q4 25
Q3 25
1.12×
Q2 25
0.90×
Q1 25
0.77×
Q4 24
Q3 24
0.67×
Q2 24
1.77×
Q1 24
1.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons